C ardiovascular disease causes myocyte death and the reduction in the number of functional cardiac myocytes ultimately results in poor cardiac pump function and heart failure. Because adult cardiac myocytes have extremely limited proliferative capacity, replacing lost myocytes and their supporting vasculature will require the use of cells with the capacity to differentiate into the lost cell types. Several molecular and cellular approaches have been tested to replace lost cardiomyocytes and restore myocardial function after injury. Research from several laboratories, including ours, suggests that stem cells hold immense potential for cardiac repair and regeneration. [1] [2] [3] [4] Clinical use of adult stem cells is a reality today and many stem cell types, including bone marrow-derived mesenchymal stem cells (MSCs), 5 bone marrow cells, 7, 8 cardiac-derived cardiac progenitor, 6 and cardio-sphere derived cells 9 have been tested. The beneficial effects of tested cell therapies on cardiac structure and function have been modest and most studies to date have not been adequately powered to document efficacy. The emerging consensus from these studies suggests that the donated stem cell population falls short of fully restoring normal cardiac functional capacity because of a combination of issues, such as poor survival, lack of proliferation, engraftment, and differentiation. In addition, it seems that much of the benefit derived from cell therapy has come from the release of paracrine factors acting on the host myocardium rather than from differentiation of infused/injected stem cells into new cardiac tissue.
after injection and those that do survive fail to engraft in the damaged organ. 11 Current beneficial effects of cellular therapy seem to be mediated by the remaining of 1% of the donated population a week after transplantation. Improving the retention of donated stem cells should enhance their reparative effects. Another stem cell feature that could augment their reparative properties would be enhanced proliferation, which would increase the number of engrafted cells. Furthermore, a hypothesis of the current research is that enhanced myocardial repair is contingent on communication between injected stem cells and the cells within the heart. [12] [13] [14] This communication could come from secretion of cardioprotective factors (paracrine signaling) or from direct contact between stem cells and cardiomyocytes. Paracrine signaling between the donated stem cell population and host myocardium is important to promote cell-based myocardial repair. 15, 16 Stem cells with enhanced paracrine signaling should enhance cardiac repair. In addition, improved electric coupling between injected stem cells and cardiac myocytes, via gap junctions, could enhance or induce the commitment of stem cells to the cardiac lineage, and thereby improve their ability to repair the damaged heart.
Recently, we have shown, in a mouse myocardial infarction (MI) model, that cortical bone-derived stem cells (CBSCs) improve cardiac function after MI. However, CBSCs have not been fully characterized and their reparative potential relative to other stem cell types currently being tested in human trials is unknown. In this study, 2 stem cell types are used as standards to evaluate the potential of CBSCs. Cardiac-derived stem cells (CDCs) are used as a gold standard because they are resident cardiac stem cells and are primed to commit toward cell types that constitute the heart. In addition, MSCs are used for comparison, as they are isolated from bone marrow, lying in close proximity to hard bone that is the source for CBSCs. We aim to investigate if CBSCs share any properties with MSCs. This research will determine if CBSCs have enhanced proliferation, survival, and differentiation versus the 2 other stem cells types (CDCs and bone marrow MSCs). Our results show proof of concept that these cells have properties that support the idea that they have greater potential to repair the damaged heart than other cells that are currently being tested clinically.
Methods

Cortical Bone Stem Cell Isolation
Cortical bone stem cells (CBSCs) were isolated from biopsies obtained from hard bone of miniswine (Gottingen, female 4-6 months of age), or tibias and femurs of enhanced green fluorescent protein (eGFP)+C57BL/6 mice. Bone marrow was flushed out before taking the bone biopsies (3 mm). The bone biopsy was digested in collagenase for an hour and passed through 100 and 40 μm. The remaining cells were plated in CBSCs growth media until homogenous population of stem cells was obtained as described previously. 
Cardiac-Derived Stem Cell Isolation
Heart biopsy was obtained from Gottingen miniswine or eGFP+C57BL/6 mice for isolation of CDCs. Heart tissue was digested in collagenase and c-kit sorted as described earlier. 1 CDCs were cultured in CBSCs media.
Mesenchymal Stem Cells Isolation
MSCs were isolated from swine and obtained from University of Miami. The cells were cultured in DMEM (Invitrogen, containing 20% fetal bovine serum [Gibco Life Technologies, NY], 1% Penicillin/Streptomycin/l-glutamine (Gibco Life Technologies) as described earlier.
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Proliferation and Survival Assays
CyQuant assay involves plating cells in quadruplicate (2000 cells/ well) in a 96-well plate and incubation CyQuant reagent (Life Technologies, CA) as previously described.
2 pCBSCs, CDCs, and MSCs were plated in a 6-well dish (30 000 cells/well) and incubated in their respective medium without serum overnight and then treated with 10, 20, 30, 40 , and 50 μmol/L H 2 O 2 overnight. Cell death was confirmed by visualizing the cells under a light microscope before collection. Cells were harvested and stained with Annexin-V (Life Technologies) and propidium iodide (Life Technologies) according to manufacturer's protocol. Data were acquired with the BD Caliber and analyzed by Flow Jo software (BD Biosciences). All experiments were done using cells from passage numbers around 12 to 18.
Morphometric Analysis
pCBSCs, CDCs, and MSCs were plated in a permenox chamber slides, and bright field images were obtained using Nikkon TS100 microscope. Cell morphology was measured by tracing the outline of the cells using ImageJ software; 200 cells were used to quantify cell morphology per stem cell type.
Real-Time Reverse Transcriptase-Polymerase Chain Reaction
Total RNA was isolated from multiple stem cell type using Quick-RNA MiniPrep (Zymo Research, CA) according to manufacturer's protocol. cDNA was prepared using iScript cDNA Synthesis Kit (Bio Rad, CA). Real-time polymerase chain reaction was performed on samples in triplicate using iQ SYBER Green (Qiagen, CA). Primer sequences are listed in online Table II .
Lineage Commitment and Immunostaining
For differentiation pCBSCs, CDCs, and MCS were treated with dexamethasone 10 nmol/L for 7 days as previously described. 2 Cells were fixed with 4% paraformaldehyde and immunostaining was performed as described earlier stained for paracrine factors, including fibroblast growth factor (bFGF; ABCAM, Cambridge MA), hepatocyte growth factor (HGF; ABCAM), insulin-like growth factor (IGF-1; ABCAM), vascular endothelial growth factor (VEGF; ABCAM), platelet-derived growth factor (ABCAM) before and after differentiation.
Chemotaxis in Response to Growth Factors
pCBSCs, CDCs, and MSCs were exposed to different concentrations (50, 100, and 200 ng/mL) of bFGF, HGF, VEGF, IGF-1, stromalderived growth factor 1, platelet-derived growth factor, and transforming growth factor-β (TGF-β; Peprotech; Rocky Hill, NJ) for 24 hours in a Boyden chamber (Biocell Laboratories, CA). The migration was estimated by light microscopy. The migrated cell were stained and dissociated following manufacturer's guidelines. The measurements were obtained at OD 560 using plate reader (Tecan, CA). Cytoplasmic Ca 2+ was measured as described earlier.
Nonstandard Abbreviations and Acronyms
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RNA Sequencing
The sequencing libraries were constructed from 500 ng of total RNA using the Illumina's TruSeq RNA Samplepre kit V2 (Illumina) following the manufacturer instruction. The fragment size of RNAseq libraries was verified using the Agilent 2100 Bioanalyzer (Agilent) and the concentrations were determined using Qubit instrument (LifeTech). The libraries were loaded onto the Illumina HiSeq 2500 at 6 to 10 pmol/L on the rapid mode for 2×100 bp paired end read sequencing.
The fastq files were generated on the Illumina's BaseSpace service or locally using the Casava software package for further analysis.
Statistical Analysis
All data were expressed as a mean±SEM. Comparison between multiple groups were done by 1-or 2-way ANOVA. P<0.05 was considered as statistically significant. Statistical analysis was performed using GraphPad prism version 5.0 software.
Results
Characterization of CBSCs
CBSCs were isolated from Gottingen miniswine (sCBSCs) to confirm the feasibility of CBSCs isolation, purification, and expansion from a large animal model. Immunophenotypic characterization of sCBSCs documented the presence of a distinct cell surface receptor signature compared with CDCs and MSCs. RNA-sequencing data revealed sCBSCs, which have a unique marker profile with high expression of CD55, integrin β4, integrin β3 (CD61), CD82, NT5E (CD73), and endoglin, compared with CDCs and MSCs (Online Figure I ). sCBSCs express lower levels of CD59 compared with CDCs and MSCs. Expression of CD96 was extremely low in sCBSCs and CDCs, compared with MSCs. Similarly, CD248 was expressed on sCBSCs and CDCs. All 3 cells types expressed CD276, CD109, and were negative for PTPRC (protein tyrosine phosphatase, receptor type, C; also known as CD45) and CD11b (Online Figure I ). Expression of some of these markers was also confirmed using real-time reverse transcriptase polymerase chain reaction analysis (Online Table I ). Single-cell cloning was performed by FACS (fluorescence-activated cell sorting) sorting in a 96-well dish. Each well was carefully assessed under a microscope to confirm the presence of a single cell per well. CBSCs could generate colonies within 5 to 7 days (Online Figure II) . These data established that despite the close proximity of origin for MSCs and CBSCs, CBSCs exhibit an extremely distinct cell surface profile and are highly clonogeneic.
Morphology and Growth Kinetics of CBSCs
sCBSCs isolated exhibited a unique morphometry compared with CDCs and MSCs. CBSCs were thin spindle-shaped cells and share some similar morphology with CDCs. MSCs were broad flat cells with distinct differences in morphology when compared with CBSCs ( Figure 1A -1C), as seen under bright field microscopy. There were significant differences in the overall area of CBSCs versus CDCs and MSCs. In addition, CBSCs showed significantly reduced roundness compared with CDCs and MSCs ( Figure 1D -E). sCBSCs showed significantly increased proliferation at day 3 compared with CDCs (P<0.001) and MSCs (P<0.001; Figure 1F ). Concurrently, the enhanced accumulation of sCBSCs in S-phase (20.50%) together with a significant reduction of the G1-phase (64.6%) compared with CDCs (G1-phase 79.7%, S-phase 11.6%) and MSCs (G1-phase 83.7%, S-phase 7.95%; Figure 1G ) documents differences in the proliferative potential of CBSCs versus CDCs and MSCs. Genes involved in proliferation and cell cycle clustered in a heat map indicates increased expression of cyclin D2, guanine nucleotide-binding protein-like 3. Similarly, replication protein A3 that plays an essential role both in DNA replication and in the cellular response to DNA damage, was upregulated in CBSCs. CDK2A (cylin-dependent kinase 2A), involved in G1-S transition in a cell cycle, was also increased in CBSCs compared with CDCs and MSCs ( Figure 1H ). Taken together, these data suggest that CBSCs possess higher proliferative capacity than CDCs and MSCs. Figure 2E ). These data suggest that sCBSCs have a greater ability that the comparator cells to withstand apoptotic stimuli and like CDCs they enhance myocyte survival under hostile conditions.
There are new data suggesting that the cardioprotective effects of stem cells could result from modulation of the immune response. sCBSCs expressed extremely low levels of interleukin (IL)-1α that is mainly responsible for the production of inflammation and secreted phosphoprotein-1 that is expressed on immune cells, including macrophages, neutrophils, dendritic cells, and T and B cells, with varying kinetics (P<0.001 CBSCs versus MSCs). CD86, a protein present on antigen presenting cells that provides signals to activate T cells, was expressed at low levels in sCBSCs when compared with CDCs and MSCs. IL-33 that is thought to drive expression of T-helper cells was also expressed at lower levels in CBSCs (P<0. CDCs; Figure 2F ). There was no significant difference in expression of immune markers detected in undifferentiated or differentiated states in sCBSCs. These preliminary data suggest that CBSCs will influence the immune response after cardiac injury.
Migration of stem cells toward sites of injury is important to augment cardiac repair after injury. Several growth, paracrine, and autocrine factors are released by stem cells if/when they arrive at the site of injury. 20 sCBSCs, CDCs, and MSCs all showed chemotaxis for most of the paracrine factors, including bFGF, HGF, VEGF, IGF-1, stromal-derived growth factor 1, platelet-derived growth factor, and TGF-β. CBSCs showed increased migration toward TGF-β compared with CDCs and MSCs (CBSCs versus CDCs and MSCs; P<0.001; Figure 2G ). To test the migration and engraftment capacity of donor stem cell population in response to injury in an in vivo setting, CBSCs and CDCs isolated from eGFP+C57/BL6 mice were injected in mice after MI. Mice that received cortical bone stem cells isolated from mice, showed robust mobilization from border zone to injury site versus CDCs that were present as a cluster in a border zone area at 2 weeks. Cortical bone stem cells isolated from mice showed engraftment in the infarct area with some cells showing organization after 2 weeks ( Figure 2H ).
Paracrine Factor Expression and Enhanced Lineage Commitment
Stem cells injected into injured hearts could improve cardiac function by the secretion of paracrine factors that stimulate cardiomyocyte survival or angiogenesis, by recruitment of endogenous stem cells that enhance cardiac repair into the damaged region, or by differentiation into new cardiac tissue (blood vessels and myocytes). We assessed paracrine factors known to play a role in cardiac repair process, including bFGF, HGF, IGF-1, VEGF, and platelet-derived growth factor, in sCBSCs, CDCs, and MSCs via immunolabeling before and after treatment with differentiation media. The expression levels of these paracrine factors changed in response to differentiation stimuli. sCBSCs expressed high levels of HGF, VEGF, and PGDF after differentiation with dexamethasone treatment ( Figure 3E ). Markers of cardiac lineage commitment, including GATA-4 and MEF2C (myocyte enhancer factor 2C; transcription factors that play an important role in cardiac development), von Willebrand factor (involved in vasculogenesis), and cardiac troponin T (myogenesis) were increased in sCBSCs relative to MSCs and CDCs after dexamethasone treatment. These results were confirmed by quantitative real-time polymerase chain reaction analysis (Figure 3A-D) . Morphological remodeling (flattening of cells) was observed after dexamethasone treatment in CBSCs as previous observed in CDCs. 
Functional Gap Junctions With the Neighboring Myocytes
Improved cardiac function induced by autologous cell therapy is thought to involve integration of transplanted stem cells with the host myocardium. Direct interaction of the transplanted stem cells with the host myocardium could be involved in cardioprotection. The potential of sCBSCs, CDCs, and MSCs to form cell-cell connections with the host myocardium was assessed by coculture with AVMs. DIL-labeled sCBSCs were cocultured with isolated AVMs for a week. In coculture, myocytes formed connexin-43 positive connections with CBSCs within 2 to 3 days (Online Figure III) . Functional gap junctions between the 3 stem cell types and AVMs were significantly increased during the first week in coculture. We confirmed the presence of direct cellular communication between AVMs and CBSCs, CDCs and MSCs using a fluorescence recovery after a photobleaching assay. FITC (fluorescein isothiocyanate)-calcein fluorescence signal of the photo-bleached AVM recovered during the 15 minutes recovery period, whereas the calcein signal of the neighboring stem cells declined indicating a functional gap junction with neighboring AVMs (Figure 4 ). In addition, electric coupling of CBSCs to AVMs was demonstrating by recording membrane potential fluctuations in CBSCs that occurred during contractions of neighboring AVMs (n=3). These likely occurred by conduction of local currents from AVMs into CBSCs via gap junctions (Online Figure IV) .
Differential Responses to Histamine and ATP Stimulus Between CBSCs, CDCs, and MSCs Measured by Cytosolic Calcium Levels
Changes in cytosolic Ca 2+ were measured in sCBSCs, CDCs, and MSCs after exposure to histamine and nucleotide (ATP). The number of cells responding to histamine was greater (78.25%) in CBSCs than in MSCs (31.6%; P>0.01). CDCs did not response to histamine (Figure 5A-D) . CBSCs, CDCs, and MSCs also had different responses to 200-μmol/L ATP. ATP caused a transient rise in Ca 2+ followed by a steady state elevation. The relative Ca 2+ peak was greatest for CBSCs followed by CDCs and then MSCs, respectively (Figure 5E-G; 100% of CBSCs and CDCs showed response to ATP compared with 58% for MSCs (P<0.05 CBSCs and CDCs versus MSCs; Figure 5H ).
Discussion
Cellular therapy for patients with heart failure has progressed from preclinical studies to early clinical trials during the past decade. 6, 9, 21 However, results from cellular therapy trials using multiple stem cell types have shown little or no positive effect on cardiac structure and function. 10 Improved cardiac function is contingent on many factors, including the successful delivery of the therapeutic agent to the injury site. The goals of cell therapy for injured hearts include regeneration of new tissue in place of damaged myocardium, 22 salvaging myocytes that are at risk of death 23 or immunomodulation of the inflammatory response after cardiac insult to improve post MI remodeling. 24 Important factors for enhanced regeneration/repair that we explored in this study include the potency/ potential of the transplanted cells, 25 their capacity to survive, 26 migrate and proliferate, 27 engraft and make connections to the existing neighboring myocytes in the ischemic cardiac milieu. We simultaneously investigated stem cell-derived paracrine, autocrine and growth factors that play an important role in salvaging the existing myocytes and restrict infarct expansion to improve cardiac function.
In this study, a novel population of stem cell from the bone stroma has been characterized and compared with more extensively studied stem cell types that are currently being used for clinical trial, including CDCs and bone marrow-derived MSCs. Stem cell-derived from cortical bone (CBSCs) express a distinctive cell surface marker profile, clearly separating them from MSCs derived from bone marrow and CDCs that was used as a standard in the study (Online Figure I) . CBSCs also exhibit different morphology when compared with MSCs and share some similarities with CDCs (Figure 1) . A unique marker profile and differences in appearance confirm the novelty of CBSCs.
Poor survival and marginal retention of adoptively transferred cells into the pathologically challenged heart is widely reported, massive loss of donated stem cells, and failure to engraft in the damaged organ occurs within the first few days after delivery and therefore pose a challenge in the field. 11 The optimal stem cell should be able to endure apoptotic, necrotic and hypoxic conditions prevalent in host environment for desirable results. CBSCs and CDCs showed enhanced survival after an apoptotic challenge compared with MSCs. Also, CBSCs and CDCs increased the survival of AVMs in a coculture experiment, suggesting that their known beneficial effects are not only related to their enhanced survival capacity but also to an ability to salvage myocytes at the site of injury that have survived the acute insult (Figure 2 ). In addition to low survival, the poor mobility and engraftment of donated stem cell could also impede their therapeutic potential. CBSCs showed enhanced capacity to migrate from the injection site to the infarct border zone in vivo and engraft in the infarct zone within 2 weeks ( Figure 2H ). This enhanced engraftment may be because of their improved secretion of paracrine factors or the response to the factors produced at the site of injury. To achieve more meaningful results from cellular therapy, donated stem cells that can proliferate should be more effective Stem cells could modulate the immune response in the injured heart to improve cardiac repair after injury. Tissue injury results in release of proinflammatory cytokines that triggers a cascade of events, involving attraction of T lymphocytes to the site of injury that then secrete proinflammatory factors, which increase influx of other immune cell types, including T, B, and antigen-presenting cells to the site of injury. 28 However, prolonged intense inflammation can result in further damage eventually leading to organ failure. Immune modulatory properties of stem cells may promote resolution of inflammation and facilitate tissue repair. Previously, MSCs have been well reported to have a beneficial role in immune modulation and are known to be immunoprivileged. 29 Therefore, we aimed to determine if CBSCs possess markers that suggest that they are be involved in altering the immune response to injury. CBSCs expressed extremely low levels of IL-1α (interleukin 1 alpha), secreted phosphoprotein-1, and IL-18 compared with MSCs and CDCs. These factors are known to play a proinflammatory role and trigger T, B cells, and antigen-presenting cells responses. IL-1α is mainly produced by activated macrophages and neutrophils and is known to play central role in mediating an immune response. 30 Diminished expression of these factors suggests CBSCs could play a positive role in modulating the immune response, which might lead to improve wound healing cardiac repair after infarction. Concurrently, CBSCs also express increased TGF-β levels. TGF-β can inhibit T-lymphocyte proliferation 31 and it has been demonstrated that anti-TGF-β antibodies can restore T-lymphocyte proliferation. 32 These preliminary findings suggest that CBSCs might have a potential role in regulating immune suppression after CBSCs delivery.
Stem cell-mediated myocardial repair could involve communication between the injected stem cells and the cells within the heart. 12, 14, 33 Communication between the stem cells and myocytes can be achieved by secretion of cardioprotective or angiogenic factors (paracrine signaling) 34 or from direct stem cell, cardiac myocyte, contact. 35 CBSCs can form direct gap junctional connections with AVMs that could enhance their reparative properties. Stem cells with enhanced paracrine signaling should be able to augment cardiac repair mitigating direct protection 36 on the existing myocyte or stimulating the endogenous pool of stem cells to replicate and contribute in repair processes. 37 After lineage commitment, all 3 stem cell types expressed paracrine factors known to be responsible for improvements in cardiac function after stem cell transplantation (Figure 3 ). In our previous published findings, we have shown that, after 24 hours and 2 weeks of CBSCs transplantation, levels of paracrine factors including bFGF and VEGF are upregulated 1 and could account for enhanced neovascularization previously observed in CBSCs-injected animals after ischemic insult. Similarly, these paracrine factors are also known to have protective effects on heart. This protective effect can be on myocytes and vessels that can limit the expansion of infarct area after cardiac injury, leading to improvement in cardiac function. Simultaneously, CBSCs also have the ability to differentiate into new myocytes and vessels to improve cardiac function after MI in a murine model. 1 Improved electric coupling between injected stem cells and cardiac myocytes via gap junctions could enhance the commitment of stem cells to the cardiac lineage and enhance their ability to repair the damaged heart. CBSCs, CDCs, and MSCs all couple to AVMs making function gap junctions for direct cellular communication as shown by a fluorescence recovery after photobleaching assay (Figure 4) . To initiate the reparative process, stem cells must respond to various stimuli and our results show that CBSCs can respond to inflammatory cytokines as previously reported in other stem cell types, including cardiac progenitor cells 38 and embryonic stem cells. 39 Our results reveal that each cell type responds differently to the inflammatory cytokines ATP and histamine. Both of these cytokines activate plasma membrane receptors, which elicit downstream IP3R (inositol trisphosphate receptor)-mediated calcium signaling. ATP and histamine play important roles in inflammatory signaling and contribute to cardiac repair after MI. 40, 41 Our results indicate that unlike CDCs and MSCs, CBSCs respond to both ATP and histamine making them prime candidates to initiate cardiac repair processes after MI.
In summary, our study delineated unique characteristics of stem cells isolated from cortical bone. CBSCs express distinctive cell surface marker profiles, which clearly distinguish them from MSCs and CDCs. A meticulous comparison of CBSCs with CDCs revealed that despite of CBSCs noncardiac origin, they are equivalent to or better than CDCs in terms of proliferative, survival, and cardiac lineage commitment capacity. Preliminary findings also highlighted the prospective role of CBSCs in modifying the immune response; however, detailed in vivo studies are needed to fully understand their immunemodulating properties. Furthermore, CBSCs secrete a host of paracrine factors and possess the ability to migrate to the site of injury and engraft, which should reduce damage and enhance repair after ischemic insult. Our findings suggest that CBSCs may be superior to MSCs or CDCs in terms of their ability to repair the heart that has been injured by ischemic disease.
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